AIQ Solutions has announced a major step forward in the effort to address late-stage cancer, following the approval of a new Category III Current Procedural Terminology (CPT) code by the American Medical Association (AMA). The newly approved code formally describes the distinctive analytical output produced by AIQ’s TRAQinform IQ technology. The decision comes after several years of clinical validation, regulatory engagement, and operational preparation carried out by AIQ. With this development, the company aims to expand oncologists’ access to advanced treatment response intelligence, potentially benefiting patients who require more precise insights into how their disease is responding to therapy.
TRAQinform IQ delivers lesion-level analysis that enables clinicians to observe treatment response heterogeneity earlier and with greater clarity than conventional imaging-based evaluations. By examining individual lesions rather than relying solely on broader imaging assessments, the technology provides a more detailed understanding of how different parts of a tumor burden respond to therapy. For individuals living with advanced cancer, this deeper level of analysis can influence treatment strategy, helping physicians make decisions that may improve the likelihood of better clinical outcomes.
“This CPT code represents a critical step toward broader clinical adoption of technology that can transform care for patients with advanced cancer,” said Eric Horler, President and CEO of AIQ Solutions. “By formally recognizing the unique analysis our platform provides, the AMA has helped pave the way for oncologists to access intelligence that can guide more timely and effective treatment decisions.” The recognition also strengthens AIQ’s engagement with hospitals, payers, and strategic partners, supporting the company’s efforts to broaden the reach of its technology across the healthcare ecosystem.
“For clinicians and patients, this matters,” says Glenn Liu, MD, AIQ Co-Founder and Chief Medical Officer. “Understanding how each lesion is responding differently to treatment can profoundly change treatment recommendations. More informed decisions result in confident decisions that improve patient care.” The approval is particularly notable given its rarity. While roughly 1,400 AI-enabled software medical devices have received clearance or approval from the U.S. Food and Drug Administration (FDA), fewer than 30 CPT codes have been granted for procedures involving software-enabled technologies. The addition of AIQ’s analysis to this select group underscores the company’s distinct clinical contribution within oncology.
